Claim

In women with lupus nephritis of reproductive potential, requiring two consecutive low-activity visits (for example, low proteinuria plus stable creatinine and no recent extra-renal flare) before mycophenolate withdrawal will reduce preconception and first-trimester severe maternal flare compared with strategies that focus mainly on a fixed washout interval.

Why this is plausible

Current reproductive guidance correctly treats mycophenolate as teratogenic, but washout alone does not solve the bedside problem. The maternal hazard is not just drug exposure; it is withdrawing an effective maintenance therapy before the disease is truly quiet. A stability-based transition criterion should outperform calendar-based switching because it captures biologic readiness for de-escalation.

Testable prediction

In a prospective multicenter autoimmune pregnancy registry, a protocol using two consecutive low-activity visits before switching from mycophenolate to a pregnancy-compatible regimen will show:

1. lower severe flare rates from preconception through 20 weeks gestation,
2. no increase in fetal exposure events,
3. better net maternal-fetal benefit than fixed washout timing alone.

Suggested study design

• Population: reproductive-age lupus nephritis patients on mycophenolate planning pregnancy
• Exposure: stability-based transition protocol vs fixed-time transition protocol
• Primary outcome: severe renal or systemic flare by 20 weeks gestation
• Secondary outcomes: fetal exposure events, miscarriage, creatinine rise, proteinuria rebound, hospitalizations
• Analysis: target-trial emulation with time-updated confounding control

Falsification

This hypothesis is weakened if stability-based transition shows no flare reduction after adjustment for baseline nephritis severity, prior flares, and background steroid burden.

References

1. Sammaritano LR, et al. 2020 ACR Reproductive Health Guideline. DOI: 10.1002/acr.24130
2. Götestam Skorpen C, et al. EULAR antirheumatic drugs before/during pregnancy. DOI: 10.1136/annrheumdis-2015-208840
3. Perez-Aytes A, et al. Prenatal Exposure to Mycophenolate Mofetil: An Updated Estimate. DOI: 10.1016/S1701-2163(16)34622-9